Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2003, Vol. 8 ›› Issue (4): 428-430.

Previous Articles     Next Articles

Interference of valsartan on bloodPressure andPlasma angiotensinⅡ , aldosterone in salt sensitive essential hypertensivePatients

HUli-Qun, CAI Qi-Yun, WANG Wei-Dong, lIU Jun   

  1. Department of Cardiology,leader Ward,AnhuiProvince Hospital,Hefei 230001,Anhui,China
  • Received:2002-11-08 Revised:2003-02-21 Online:2003-08-26 Published:2020-11-19

Abstract: AIM: To investigate the interference of valsartan on bloodPressure andPlasma angiotensinⅡ(angⅡ),aldosterone(ALD)in salt sensitive essential hypertensivePatients.METHODS: Eighty-four adult hypertensivePatients were enrolled in study,and the salt sensitivity was determined by acute intravenous salt waterloading according to Sullvan' s criteria.The change of bloodPressure andPlasma angⅡ,and ALD were compared before and after the treatment.RESULTS: At the end of 2,4,6,and 8 weeks,patients with salt sensitive essential hypertensive(grouPss)and no salt sensitive essential hypertensive(grouPnss)were measured.The results showed that sitting systolic bloodPressure(SiSBP)was decreased by 17.5±4.3 and 11.0±1.4 mmHg,and sitting diastolis bloodPressure(SiDSP)was decreased by 17.0±3.7 and 7.3±1.1 mmHg after the treatment.It was found thatPatients showed significantly higherPlasma angⅡ andlowerPlasma ALD in grouPss and grouPnss.CONCLUSION: Valsartan can significantly control SiSBPand SiDBPfor both groups,interferedPlasma angiotensinⅡ and I aldosterone,and be more effective forPatients with salt sensitive essential hypertensive.

Key words: pharmacodynamics, valsartan, salt sensitive, hypertensive, angiotensinⅡ, aldosterone

CLC Number: